Prevalent Pseudoprogression and Pseudoresidue in Patients with Rectal Cancer Treated with Neoadjuvant Immune Checkpoint Inhibitors
Yumo Xie,Jinxin Lin,Ning Zhang,Xiaolin Wang,Puning Wang,Shaoyong Peng,Juan Li,Yuanhui Wu,Yaoyi Huang,Zhuokai Zhuang,Dingcheng Shen,Mingxuan Zhu,Xiaoxia Liu,Guangjian Liu,Xiaochun Meng,Meijin Huang,Huichuan Yu,Yanxin Luo
DOI: https://doi.org/10.6004/jnccn.2022.7071
IF: 12.6934
2023-01-01
Journal of the National Comprehensive Cancer Network
Abstract:Background: Immune checkpoint inhibitor (ICI) treatment in patients with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) tumors holds promise in reshaping organ preservation in rectal cancer. However, the benefits are accompanied by distinctive patterns of response, introducing a dilemma in the response evaluation for clinical decision-making. Patients and Methods: Patients with locally advanced rectal cancer with MSI-H/dMMR tumors receiving neoadjuvant ICI (nICI) treatment (n=13) and matched patients receiving neoadjuvant chemoradiotherapy (nCRT; n=13) were included to compare clinical response and histopathologic features. Results: Among the 13 patients receiving nICI treatment, in the final radiologic evaluation prior to surgery (at a median of 103 days after initiation of therapy), progressive disease (n=3), stable disease (n=1), partial response (n=7), and complete response (n=2) were observed. However, these patients were later confirmed as having pathologic complete response, resulting in pseudoprogression and pseudoresidue with incidences of 23.1% (n=3) and 76.9% (n=10), respectively, whereas no pseudoprogression was found in the 13 patients receiving nCRT. We further revealed the histopathologic basis underlying the pseudoprogression and pseudoresidue by discovering the distinctive immune-related regression features after nICI treatment, including fibrogenesis, dense lymphocytes, and plasma cell infiltration. Conclusions: Pseudoprogression and pseudoresidue were unique and prevalent response patterns in MSI-H/dMMR rectal cancer after nICI treatment. Our findings highlight the importance of developing specific strategies for response evaluation in neoadjuvant immunotherapy to identify patients with a good response in whom sphincter/organ-preserving or watch-and-wait strategies may be considered.